836
A 51-year-old man developed type 1 diabetes mellitus following 24 weeks of treatment with recombinant alpha-2b peginterferon plus ribavirin for chronic hepatitis C.
 ( adverse event: developed ,  A 51-year-old man: Subject, 51-year-old: Subject.Age, man: Subject.Gender, type 1 diabetes mellitus: Effect, 24 weeks of treatment with recombinant alpha-2b peginterferon plus ribavirin: Treatment, 24 weeks: Treatment.Time_elapsed, recombinant alpha-2b peginterferon: Treatment.Drug, ribavirin: Treatment.Drug, chronic hepatitis C.: Treatment.Disorder, recombinant alpha-2b peginterferon: Combination.Drug, ribavirin: Combination.Drug) 
Locate the role in the text that participated in the event based on the event type and return it in the event list. 
 Option: Event type: adverse event,potential therapeutic event, Arguments type: Treatment.Disorder,Treatment.Time_elapsed,Treatment.Dosage,Subject.Race,Treatment.Drug,Treatment.Route,Subject.Disorder,Treatment.Freq,Treatment,Effect,Subject.Population,Treatment.Duration,Combination.Drug,Subject,Subject.Age,Subject.Gender. 
Text: {0} 
Answer:
 ( adverse event: developed ,  A 51-year-old man: Subject, 51-year-old: Subject.Age, man: Subject.Gender, type 1 diabetes mellitus: Effect, 24 weeks of treatment with recombinant alpha-2b peginterferon plus ribavirin: Treatment, 24 weeks: Treatment.Time_elapsed, recombinant alpha-2b peginterferon: Treatment.Drug, ribavirin: Treatment.Drug, chronic hepatitis C.: Treatment.Disorder, recombinant alpha-2b peginterferon: Combination.Drug, ribavirin: Combination.Drug) 